When will trintellix be available in generic?

Short answer:
There isn’t a confirmed generic launch date for Trintellix (vortioxetine) in the United States yet. Most experts expect a generic version to become available sometime around 2024‑2025, but the exact timing will depend on patent expirations, any litigation that may extend those patents, and when a qualified generic manufacturer files and gets FDA approval for an Abbreviated New Drug Application (ANDA).

Why the exact date is still unclear

Because of these variables, the FDA does not release a “generic launch date” until a company actually submits the ANDA and the FDA has reviewed it.

What we do know

• Brand approval date: Trintellix (vortioxetine) was first approved by the FDA in August 2013 for the treatment of major depressive disorder.
• Patent timeline: The most robust patents (e.g., U.S. 7,352,600 and U.S. 8,212,941) expire 2025.
• Generic entry window: The typical window for a generic after patent expiry is roughly 12‑18 months for the ANDA review, so a 2025 launch is realistic if the patents expire as scheduled and no litigation delays arise.

How to stay updated

1. FDA’s Orange Book – lists drug patents and exclusivities. Check the status of Trintellix’s patents there.
2. FDA’s Generic Drug Database – once a generic is approved, it will appear here.
3. Industry news – websites like PharmaTimes or FiercePharma often report when a generic manufacturer files an ANDA.
4. Ask your pharmacist – they usually know whether a generic is on the horizon or if a specific drug is still under brand exclusivity.

Bottom line

Trintellix is still brand‑exclusive in the U.S., and the generic market is expected to open in 2024‑2025 after the expiration of the last remaining patent. Until a manufacturer submits an ANDA and the FDA approves it, the exact launch date remains uncertain. If you need a cost‑effective alternative sooner, discuss with your prescriber; they may be able to recommend a different, approved antidepressant that is already generic.